{"entity":{"id":"maha-hussain","kind":"person","name":"Maha Hussain","aka":[],"tldr":"Led PROSPER and the PROfound survival analysis, and settled the intermittent hormone therapy question with SWOG 9346.","summary":"Maha Hussain led SWOG 9346, the trial that showed intermittent androgen deprivation is not non-inferior to continuous therapy in metastatic prostate cancer, and was principal investigator of PROSPER (enzalutamide in non-metastatic CRPC) and first author of the PROfound overall survival report establishing olaparib in HRR-mutant disease. She chairs the SWOG GU committee's prostate programme.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Maha_H._Hussain","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hussain%20M%5BAuthor%5D%20prostate%20olaparib%20OR%20enzalutamide"}],"tags":["prostate","swog","parp"],"related":[],"cancers":["prostate"],"sections":[],"technologies":["parp-inhibitor","androgen-deprivation"],"targets":["parp","brca","androgen-receptor"],"drugs":["olaparib"],"companies":[],"institutions":["northwestern-lurie"],"pathways":[],"terms":[],"trials":["profound"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Genevieve E. Teuton Professor of Medicine and Deputy Director, Robert H. Lurie Comprehensive Cancer Center of Northwestern University","institutionId":"northwestern-lurie","specialisms":["Prostate cancer","PARP inhibitors","Androgen deprivation strategies","Cooperative-group trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hussain%20M%5BAuthor%5D%20prostate%20olaparib%20OR%20enzalutamide"}],"papers":[{"title":"Survival with olaparib in metastatic castration-resistant prostate cancer (PROfound)","journal":"NEJM","year":2020,"doi":"10.1056/NEJMoa2022485"},{"title":"Intermittent versus continuous androgen deprivation in prostate cancer (SWOG 9346)","journal":"NEJM","year":2013,"doi":"10.1056/NEJMoa1212299"},{"title":"PROSPER: enzalutamide in men with non-metastatic castration-resistant prostate cancer","journal":"New England Journal of Medicine","year":2018,"url":"https://doi.org/10.1056/NEJMoa1800536","doi":"10.1056/NEJMoa1800536"}],"orcid":"0000-0003-0380-9465"},"route":"/people/maha-hussain/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"technology":[{"id":"androgen-deprivation","kind":"technology","name":"Androgen deprivation & AR pathway inhibitors","route":"/technologies/androgen-deprivation/"},{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/"}],"target":[{"id":"androgen-receptor","kind":"target","name":"Androgen receptor","route":"/targets/androgen-receptor/"},{"id":"brca","kind":"target","name":"BRCA1 / BRCA2 (HRD)","route":"/targets/brca/"},{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"}],"institution":[{"id":"northwestern-lurie","kind":"institution","name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University","route":"/institutions/northwestern-lurie/"}],"trial":[{"id":"profound","kind":"trial","name":"PROfound","route":"/trials/profound/"},{"id":"prosper","kind":"trial","name":"PROSPER","route":"/trials/prosper/"}]}}